ArticleJournal of pharmaceutical health care and sciences2025
Impact of coronavirus disease on the incidence rate of methicillin-resistant Staphylococcus aureus among hospitalized patients with lung cancer: a nationwide retrospective cohort study in Japan.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- MRSA nasal carriage among Taiwanese senior high school students and a narrative review of local metadata.New microbes and new infections · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with lung cancer are at increased risk for methicillin-resistant Staphylococcus aureus (MRSA) infection, which prolongs treatment and worsens prognosis. Therefore, preventing MRSA infection is critically important in this population. We aimed to investigate whether the incidence rate of MRSA among patients with lung cancer declined after the coronavirus disease (COVID-19) pandemic, owing to the widespread reinforcement of hand-rub use.
methodsWe conducted a nationwide, retrospective, interrupted time-series analysis using a claims database in Japan Medical Data Vision. Hospitalized patients diagnosed with lung cancer between December 2016 and August 2022 were followed for 6 months. MRSA was identified using International Classification of Diseases, 10th Revision, codes in combination with a same-month prescription for an anti-MRSA agent. The incidence rate of MRSA among patients with lung cancer was compared between the pre-COVID (December 2016-April 2020) and post-COVID (April 2020-August 2022) periods using segmented Poisson regression with Newey-West errors and seasonal adjustment.
resultsAmong 93,508 eligible patients, 364 developed MRSA. The pre-COVID slope for the incidence rate of MRSA among patients with lung cancer was flat (0.20 per 1,000 person-years/year), whereas the post-COVID slope declined to -8.97 per 1,000 person-years/year. The slope difference (-9.17 per 1,000 person-years/year) indicates a sustained decline in the incidence rate of MRSA among this population after April 2020.
conclusionsThe incidence rate of MRSA among hospitalized patients with lung cancer decreased steadily after the COVID-19 pandemic. These findings suggest that routine hospital-wide infection control measures implemented during the pandemic may yield lasting benefits even in the absence of targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.